11:17 EDT Avidity jumps 3% to $39.47 after FT report of takeover approach
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences trading halted, volatility trading pause
- Avidity Biosciences’ Phase 3 Study Update: Del-desiran for Myotonic Dystrophy
- Avidity Biosciences completes enrollment in Phase 3 HARBOR clinical trial
- Avidity Biosciences Gains FDA Breakthrough Therapy Designation
- Avidity Biosciences receives FDA BTD for delpacibart zotadirsen